Braun Stacey Associates Inc. boosted its position in Encompass Health Corporation by 9.3% during the third quarter, acquiring an additional 18,967 shares to reach a total holding of 223,673 shares. At quarter end, the stake represented approximately 0.22% of Encompass Health’s outstanding shares and carried a reported value of $28.41 million. This move underscores growing confidence among institutional investors in Encompass Health’s post-acute care platform and its ability to generate consistent cash flow.

Several major institutions initiated or expanded positions in Encompass Health across the first and second quarters. Norges Bank established a new stake valued at $139.54 million, while Congress Asset Management Co. and 8 Knots Management LLC added positions worth $92.69 million and $78.64 million, respectively. Strs Ohio and Marshall Wace LLP also entered the register with new investments of $34.36 million and $34.72 million. Collectively, hedge funds and other institutional investors now account for over 97% of shares outstanding, highlighting the stock’s prominence in large-cap healthcare portfolios.

Research firms have turned more bullish on Encompass Health in recent weeks. Raymond James upgraded to a “strong-buy” rating, and Wall Street Zen raised its recommendation from hold to buy. UBS Group lifted its target from 140.00 to 150.00, reflecting expectations for accelerating revenue growth driven by increased patient volumes in both rehabilitation hospitals and home health services. Despite Zacks Research moderating from strong-buy to hold, the consensus among ten analysts remains positive, with an average target of 142.86 and eight buy ratings against a single hold.

In its latest quarterly report, Encompass Health delivered EPS of 0.93 and generated revenue of $136.3 million, translating into a 17.8% return on equity and a net margin of 9.3%. The company reaffirmed its full-year guidance range of 3.83–4.19 EPS, while consensus estimates now call for 4.80 EPS for the current fiscal year. Key balance sheet metrics include a current ratio above 1.1 and a debt-to-equity ratio below 0.8, indicating ample liquidity and moderate leverage to support further expansion.

Encompass Health declared a quarterly dividend of 0.19 per share, payable January 15th to shareholders of record as of January 2nd. This distribution equates to an annualized payout of 0.76 and represents a payout ratio of approximately 14.4%. The stable dividend policy aligns with management’s focus on returning capital to shareholders while retaining flexibility for strategic investments in new inpatient rehabilitation hospitals and home health platforms.